Nadine Wolgast1,2,3*, Thomas Beder1,2,3*, Mayukh Mondal2,4*, Wencke Walter, PhD5, Stephan Hutter, PhD5*, Sonja Bendig1,2,3*, Jan Kässens1,3*, Björn-Thore Hansen3,6,7*, Katharina Iben1,2,3*, Barz Malwine1,2,3*, Martin Neumann, MD1,2,3*, Nicola Goekbuget, MD8, Claudia Haferlach, MD5, Monika Brüggemann, MD1,2,3*, Claudia D Baldus, MD1,2,3*, Alina M. Hartmann2,3,9* and Lorenz Bastian1,2,3*
1Medical Department II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
2Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
3University Medical Center Schleswig-Holstein, University Cancer Center Schleswig-Holstein, Kiel, Germany
4Christian Albrechts University Kiel, Institute for Clinical Molecular Biology, Kiel, Germany
5MLL Munich Leukemia Laboratory, Munich, Germany
6(DFG, German Research Foundation): 413490537, Clinician Scientist Program in Evolutionary Medicine funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
7Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
8Hematology/Oncology, Goethe University Hospital, Frankfurt/M., Department of Medicine II, Frankfurt/M., Germany
9Department of Internal Medicine II (Hematology/Oncology), University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany